Concomitant diseases of patients in this trial included, but were not limited to, heart failure (12%), history of ischemic stroke (8%) and history of a MI (36%)
However, Mounjaros dual-action approach may lead to more pronounced appetite suppression in certain individuals
Tirzepatide is a dual GIP and GLP-1 receptor agonist that has transformed treatment for type 2 diabetes and obesity
Regularly monitoring your blood sugar levels can help you understand how different foods and activities affect your blood sugar, allowing you to make informed decisions
Why Medicare Doesn't Cover Weight Loss Medication # Medicare is barred from covering weight loss medication by law due to past safety concerns
Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks surpassing both semaglutide and tirzepatide in their respective pivotal trials
